<DOC>
	<DOCNO>NCT02290613</DOCNO>
	<brief_summary>Trial Design Patients borderline PAH indicate borderline mPAP value include single centre study . This clinical investigation perform Proof-of-Concept ( PoC ) investigator initiate trial ( IIT ) use prospective , randomize , double-blind , parallel group , placebo-controlled , phase IIA clinical study design . On first visit medical history obtain physical examination conduct . Moreover , electrocardiogram ( ECG ) , laboratory testing ( NT-proBNP , uric acid laboratory test ) , echocardiography rest right heart catheterization carry . If patient identify within last 6 month screen investigation right heart catheterization , measurement consider valid baseline investigation repeat . If patient fulfill inclusion criterion still suffer borderline mPAP value invite join study . The clinical investigation begin within 28 day . The prospective study comprise 6 month study period ( 180 ±2 week ) plus screen phase 28 day follow-up phase 30 ±7 day .</brief_summary>
	<brief_title>Early Treatment Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis ( SSc-APAH )</brief_title>
	<detailed_description>Treatment naïve patient SSc-APAH include investigator initiate trial ( IIT ) ass efficacy safety ambrisentan . As patient life-expectancy diagnosis untreated patient one year put forward screen identify borderline PAH patient treat PH manifest . Therapy ambrisentan reach significant improvement SSc-IPAH patient ( Galiè et al . 2008 ) . In PAH mPAP improve 15 % due ambrisentan ( Klinger et al . 2011 ) . Thus , especially patient SSc-APAH high need early diagnosis therapy . It important determine factor predictive incident SSc-APAH PH well event rate PAH PH occurrence . Early identification intervention specific modern therapy ambrisentan may improve hemodynamic , symptom , exercise capacity , quality life outcomes patient population , particular SSc-patients borderline-PAH . It consider reasonable development manifest APAH might preventable defined population SSc early pulmonary vascular change . A reliable trial test latter hypothesis perform without critical evidence defines response medical PAH-targeted therapy borderline-PAH associate disease progression manifest PAH . Due positive result treatment patient SSc-APAH , initiation proof-of-concept study justify . Previously identify patient borderline PAH indicate borderline mPAP value include single centre randomize , control , double-blind , parallel group , proof-of-concept ( PoC ) phase IIa IIT . If assessment necessary screen already make screen PH Systemic sclerosis trial ( non-drug trial , Ethics committee Heidelberg # S360/2009 ) , examination may use screen trial , long perform within give time frame screening period . On first visit patient ' medical history obtain physical examination conduct . Moreover , electrocardiogram ( ECG ) , laboratory testing ( NT-proBNP , uric acid laboratory test ) , echocardiography rest exercise right heart catheterization carry . If patient fulfill inclusion criterion still suffer borderline mPAP value invite join study . Patients ask sign inform consent form ( ICF ) initial screening conduct . Randomization perform maximum 28 day medication placebo provide . If patient identify within last 6 month baseline right heart catheterization , measurement consider valid baseline visit spare patient repetition invasive procedure . Non-invasive measurement time-frame repeat study . An 1:1 oral ambrisentan : oral Placebo randomization perform . Patients randomize either : - A treatment arm ambrisentan treatment ( 19 patient ) - A placebo arm ( 19 patient receive placebo ) . Safety tolerability control study visit end study ( day 180 ± 2 week ) . If necessary , dose adapt . As common practice clinic , patient adapt dose accord tolerability consultation ( phone personally ) one investigator .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>1. mPAP 2124 mmHg , TPG &gt; 11mmHg , PAWP &lt; 15 mmHg and/or 2 . Exercise induce elevated mPAPvalues &gt; 30 mmHg , PAWP &lt; 18 mmHg ; TPG &gt; 15 mmHg , define Saggar et al . ( 2012 ) without left heart severe lung disease systemic arterial hypertension 3 . Adult patient complete his/her 18th birthday 4 . Patients definite diagnosis Systemic Sclerosis use scleroderma criterion American Rheumatism Association 5 . SScdisease duration &gt; 3 year 6 . Able understand willing sign Informed Consent Form 7 . Negative pregnancy test start trial appropriate contraception throughout study woman childbearing potential . 1 . Any connective tissue disease ( CTD ) SSc 2 . Pulmonary hypertension ( PH ) confirm right heart catheter ( RHC ) enrolment , i.e . mPAP ≥25 mmHg rest 3 . Patients present normal mPAP value , i.e . mPAP &lt; 21 mmHg rest , ≤30 mmHg exercise , PAWP &gt; =15 mmHg rest &lt; =18 mmHg exercise 4 . Ongoing history &gt; 2 week continue use therapy consider definitive PH treatment : endothelin receptor antagonist ( ERA ; e.g . bosentan , ambrisentan ) , phosphodiesterase type 5 inhibitor ( PDE5 ; e.g . sildenafil , tadalafil , vardenafil ) , prostanoids ( e.g . epoprostenol , treprostinil , iloprost , beraprost ) soluble guanylate cyclase stimulator ( e.g . Riociguat ) . Intermittent use PDE5 inhibitor male erectile dysfunction permit . 5 . Except diuretic corticosteroid medical treatment expect change 4 week prior inclusion study entire 12week study period . 6 . Known intolerance ambrisentan one excipients 7 . Clinically significant anemia ( hemoglobin concentration le 75 % low limit normal , LLN ) 8 . Forced vital capacity ( FVC ) &lt; 60 % , forced expiratory volume first second ( FEV1 ) &lt; 65 % 9 . Severe interstitial lung disease , idiopathic pulmonary fibrosis 10 . Renal insufficiency ( glomerular filtration rate [ GFR ] &lt; 60 mL/min/1.73m2 least 3 month ) 11 . Baseline value hepatic aminotransferase ( ALT and/or AST ) &gt; 3 x upper limit normal ( ULN ) 12 . Systolic blood pressure &lt; 85 mmHg ; 13. evidence inadequately treat blood pressure &gt; 160/90 mmHg and/or blood pressure exercise &gt; 220/120 mmHg 14 . Patients refer clinically significant overt heart failure 15 . Clinically significant fluid retention 16 . Previous evidence diagnosis clinically relevant leave heart disease , i.e . least one following : Previous echocardiography estimate leave ventricular ( LV ) ejection fraction &lt; 50 % , previous history cardiogenic pulmonary edema , increase size left atrium ( &gt; 50 mm ) 17 . Known significant diastolic dysfunction associate clinical heart failure 18 . Known coronary disease significant valvular heart disease 19 . Known congenital heart defect single ventricle , transposition , Eisenmenger 20 . Known hypertrophic cardiomyopathy leave ventricular hypertrophy ( interventricular septum thickness ( IVS ) posterior wall thickness ( PWD ) &gt; 1.2 cm ) 21 . Participation clinical drug trial within 4 week prior screen study and/or schedule receive another investigational medicinal product ( IMP ) course study 22 . Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>pulmonary hypertension</keyword>
	<keyword>systemic sclerosis</keyword>
</DOC>